Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 13, Number 4—April 2007
Dispatch

Endpoints for Lymphatic Filariasis Programs

Caroline A. Grady*, Madsen Beau de Rochars†, Abdel N. Direny†, Jean Nicolas Orelus†, Joyanna Wendt*, Jeanne Radday*, Els Mathieu*, Jacquelin M. Roberts*, Thomas G. Streit‡, David G. Addiss*, and Patrick J. Lammie*Comments to Author 
Author affiliations: *Centers for Disease Control and Prevention, Atlanta, Georgia, USA; †Hopital Ste. Croix, Leogane, Haiti; ‡University of Notre Dame, Notre Dame, Indiana, USA;

Main Article

Figure 1

Microfilaremia prevalence determined by screening thick blood films before and 6–9 months after annual mass drug administration in sentinel sites in Leogane Commune, Haiti. Blood samples (20 μL) were collected from 7–9 PM.

Figure 1. Microfilaremia prevalence determined by screening thick blood films before and 6–9 months after annual mass drug administration in sentinel sites in Leogane Commune, Haiti. Blood samples (20 μL) were collected from 7–9 PM.

Main Article

Page created: June 28, 2010
Page updated: June 28, 2010
Page reviewed: June 28, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external